IART has a superior Zacks Rank (#2 Buy vs #3 Hold), significantly lower forward P/E ratio (6.61 vs 64.35), better PEG ratio (0.84 vs 2.19), lower P/B ratio (1.21 vs 8.21), and a stronger Value grade (B vs D). The company shows positive earnings estimate revisions and more attractive valuation metrics overall.
The company demonstrated solid operational performance with improved profitability metrics (adjusted EPS up 32% YoY to $0.54), expanded adjusted gross margins (64.1% vs 62.2%), and raised full-year adjusted EPS guidance. Strong execution in key segments like Tissue Reconstruction (6.4% organic growth) and successful manufacturing transitions support positive momentum, though modest organic revenue growth of 1.3% and elevated debt levels (4.1x leverage) provide some caution.
Articles that tag IART but are mainly about other companies.
Listed as a leading market player in the growing ultrasonic aspirator market with strong market demand for precision surgical technologies.
Reported strong Q1 2026 results with 35% EPS surprise, beat revenue and guidance, demonstrated robust growth in tissue reconstruction products, and stock surged 24% on earnings announcement.
Identified as a major player in the tissue engineering market benefiting from rising demand for regenerative therapies and advancements in biomaterials and tissue regeneration platforms.
Articles and sentiment ratings from Massive / Polygon. Sentiment is the provider's model rating for this company, not Gainbot's view.
Sources: Massive / Polygon daily aggregates (split-adjusted) · SEC filings via Massive · FINRA settlements via Massive · Financial Modeling Prep. Figures are dated where shown; research is informational, not investment advice. Methodology
